Zenas BioPharma (ZBIO) Free Cash Flow (2023 - 2026)

Zenas BioPharma's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$75.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 102.86% year-over-year to -$75.2 million in Q1 2026; TTM through Mar 2026 was -$210.5 million, a 52.8% decrease from a year earlier, with the FY2025 full-year figure at -$172.4 million, down 43.86% from the prior year.
• Free Cash Flow slipped to -$75.2 million in Q1 2026 per ZBIO's latest filing, from -$52.4 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$15.4 million in Q4 2023 and bottomed at -$75.2 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$37.8 million (2024), against an average of -$38.3 million.
• Across the five-year window, Free Cash Flow slumped 150.83% in 2024 and slumped 32.41% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$15.4 million in 2023, then slumped by 150.83% to -$38.6 million in 2024, then tumbled by 35.69% to -$52.4 million in 2025, then slumped by 43.47% to -$75.2 million in 2026.
• Per Business Quant, the three latest ZBIO Free Cash Flow figures stand at -$75.2 million (Q1 2026), -$52.4 million (Q4 2025), and -$41.1 million (Q3 2025).